RxDoctor Payments Data

Matthew Pugh, DO

Clinical Cardiac Electrophysiology · Chula Vista, CANPI 1306077870

Payments from drug & device makers

$36,863in general payments, 2019–2025

Across 840 payments — averaging $43.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$10K
  • Biotronik Inc.$6K
  • Biosense Webster, Inc.$5K
  • Boston Scientific$4K
  • Medtronic$3K
  • Abbott$3K
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$12,37538%
  • Travel & lodging$4,01112%
  • Food & beverage$16,04249%
  • Education$2471%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,863 in reported general payments places this provider in the 45th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$475,917
Medicare patients
469
Services billed
2,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$265,399
MultaqDronedarone Hcl53$87,448
EntrestoSacubitril/Valsartan55$72,075
XareltoRivaroxaban34$42,823
JardianceEmpagliflozin24$26,114
Colchicine70$2,410
Flecainide Acetate58$2,341
SotalolSotalol Hcl66$1,924
Metoprolol Succinate96$1,379
ClopidogrelClopidogrel Bisulfate131$1,258
Amiodarone Hcl69$983
Mexiletine Hcl11$975
Verapamil ErVerapamil Hcl27$850
Sotalol AfSotalol Hcl11$836
Pantoprazole Sodium93$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$862$265,399265 claims
Sanofi-aventis U.S. LLCMultaq$337$87,44853 claims
NovartisEntresto$200$72,07555 claims
Johnson & JohnsonXarelto$65$42,82334 claims
Boehringer IngelheimJardiance$206$26,11424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →